NEW YORK ─ PixCell Medical on Wednesday announced an agreement with Axonlab to distribute PixCell's HemoScreen point-of-care hematology analyzer in Switzerland, Austria, the Netherlands, and the Czech Republic.
Financial and other terms of the agreement were not disclosed.
HemoScreen is a five-part differential complete blood count analyzer that has been CE marked and cleared by the US Food and Drug Administration for point-of-care use. According to PixCell, the analyzer provides laboratory-quality diagnostic results within six minutes using a blood drop.
The Yokneam Ilit, Israel-based point-of-care diagnostic company said its analyzer uses lab-on-a-cartridge and machine vision technology to deliver diagnostic results. The analyzer uses a disposable cartridge preloaded with reagents, eliminates the need for routine maintenance and calibration, and does not require operation by a lab technician, PixCell said.
The hematology analyzer provides results by using 20 standard CBC parameters and flagging abnormal cells for the early detection of infection and certain cancer types, the company said.
"Making this technology available at the point of care for hospitals, medical practices, pharmacies, private laboratories, and research organizations can increase patient safety, reduce delays in receiving key diagnostic results, and support clinicians in making informed decisions," Tamara Hensel, chief sales and marketing officer at Axonlab, said in a statement.
In February, PixCell Medical said it had partnered with Finland-based Aidian to distribute PixCell's hematology analyzer in certain countries in Europe, and in January it announced the signing of an agreement with Triolab for the distribution of the analyzer in Sweden.